Avanti NanoSciences is focused on the Life Science market segments that consistently demand new and innovative technologies to further research, development and clinical capabilities.

These markets already represent a $32 billion opportunity that is rapidly growing based on the availability of new and innovative enabling technologies. Capturing market share with attractive and sustainable returns on investment is definitely achievable.

Despite their value, current technologies have significant limitations preventing their utility in broader research and diagnostic applications where rapid, accurate and cost-effective analysis of multi parameter testing is critical. Current immunological or PCR based methods do not provide a high level of sensitivity or reproducibility and are expensive and time-consuming. Various template amplification technologies provide sensitive and reproducible analysis but are limited to analyzing up to 4 to 5 genes at a time and thereby become prohibitively expensive for monitoring larger sets of expressed biomarkers.